KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Total Liabilities (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Total Liabilities for 16 consecutive years, with $4.2 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities changed 0.1% year-over-year to $4.2 billion, compared with a TTM value of $4.2 billion through Dec 2025, changed 0.1%, and an annual FY2025 reading of $4.2 billion, changed 0.1% over the prior year.
  • Total Liabilities was $4.2 billion for Q4 2025 at Alnylam Pharmaceuticals, down from $4.3 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $4.3 billion in Q2 2025 and bottomed at $2.3 billion in Q1 2021.
  • Average Total Liabilities over 5 years is $3.6 billion, with a median of $3.8 billion recorded in 2023.
  • The sharpest move saw Total Liabilities surged 150.47% in 2021, then increased 0.1% in 2025.
  • Year by year, Total Liabilities stood at $3.1 billion in 2021, then grew by 21.26% to $3.7 billion in 2022, then rose by 9.34% to $4.1 billion in 2023, then increased by 3.02% to $4.2 billion in 2024, then increased by 0.1% to $4.2 billion in 2025.
  • Business Quant data shows Total Liabilities for ALNY at $4.2 billion in Q4 2025, $4.3 billion in Q2 2025, and $4.1 billion in Q1 2025.